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Abstract
Background: The incidence of lower extremity peripheral artery disease (LE-PAD) continues to increase and
associated morbidity remains high. Despite the significant development of percutaneous revascularization
strategies, over the past decade, LE-PAD still represents a unique challenge for interventional cardiologists and
vascular surgeons.
Method: Typical features of atherosclerosis that affects peripheral vascular bed (diffuse nature, poor distal runoff,
critical limb ischemia, chronic total occlusion) contribute to the disappointing results of traditional percutaneous
transluminal angioplasty (PTA). New technologies have been developed in attempt to improve the safety and
effectiveness of percutaneous revascularization. Among these, atherectomy, debulking and removing
atherosclerotic plaque, offers the potential advantage of eliminating stretch on arterial walls and reducing rates of
restenosis.
Conclusions: This review summarizes the features and the current applications of new debulking devices.
Introduction
Peripheral artery disease (PAD) is a common manifesta-
tion of systemic atherosclerosis causing a chronic, slowly
developing, narrowing of the arteries. Lower extremity
peripheral artery disease (LE-PAD) typically affects lower
limbs with a frequency that is strongly age-related (~20%
of the population older than 55) [1]. Clinical manifesta-
tions vary from intermittent claudication (pain in the
calves while walking that goes away with rest) to critical
limb ischemia (CLI), gangrene and, ultimately, limb loss. A
significant proportion of patients with PAD have an
increased risk of stroke or myocardial infarction [2]. The
strong relationship between PAD and coronary heart dis-
ease (CHD) is the consequence of common etiology and
pathophysiology and has important prognostic implica-
tions. Hypoechoic, vulnerable, rupture-prone, plaques in
the femoral arteries represent a marker of cardiovascular
risk and are associated to higher incidence of major cardi-
ovascular events [3]. Moreover, successful revasculariza-
tion of lower limbs by percutaneous transluminal
angioplasty (PTA) improves functional status and quality
of life and, interestingly, reduces the occurrence of future
atherothrombotic events [4]. A number of pharmacologi-
cal and invasive strategies have been developed over the
last decades to improve the clinical outcomes of patients
affected by LE-PAD. A “non-interventional” management
is the first choice for patients with intermittent claudica-
tion: smoking cessation, nutritional counseling, exercise
program, strict control of diabetes and hypertension and
medication (antiplatelet agent and statins) [5,6]. Mild to
moderate benefits have been associated to other pharma-
cological agents such as pentoxyphylline and cilostazol
that resulted effective in increasing walking distance [5];
on the other hand, the intensification of antiplatelet ther-
apy by adding vorapaxar, a novel antiplatelet agent that
inhibits cellular actions of thrombin, has shown to reduce
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atherothrombotic events in patients with PAD [7]. In the
past, bypass surgery was the standard of care for patients
with severe claudication and CLI [8]. Recently, technologi-
cal advances favoured a significant evolution of percuta-
neous revascularization therapies that now can be offered
as treatment options less invasive than traditional surgery.
The optimal endovascular therapy is not well established:
there are several options including percutaneous translum-
inal angioplasty (PTA), stents, drug-coated balloons, crio-
plasty, percutaneous thrombectomy (rheolytic [9] and
aspiration thrombectomy) and atherectomy [10,11]. In
particular, the promise of atherectomy is to overcome the
limitations and complications of traditional angioplasty
such as dissection, elastic recoil, and disruption of the
internal elastic lamina, resulting in overwhelming neo-
intima and smooth muscle cell proliferation [12]. Unlike
balloons and stents, which push plaque into the vessel
wall, atherectomy offers the ability to debulk the plaque
burden within the vessel [13]. The concept of directional
and laser atherectomy is not new and was investigated
extensively in the coronary arteries and saphenous vein
bypass graft [14]. Despite previous coronary artery data
regarding atherectomy may not translate to the peripheral
vascular bed because of peculiar dynamic forces acting on
these arteries, increased awareness about percutaneous
treatment of LE-PAD favoured the development of new
debulking devices. Various atherectomy methods are avail-
able including plaque excision (directional) atherectomy,
laser atheroablation, rotational aspiration/atherectomy and
orbital atherectomy. Although data from randomized clin-
ical trials are lacking, this review summarizes the current
approach to peripheral atherectomy based on evidences
from multicenter prospective registries and describes the
mechanism of action of currently available atherectomy
devices.
Anatomical features
Atherosclerosis affecting lower limbs has some specific
features: diffuse involvement, superimposed calcification,
high incidence of progression to total occlusion, large pla-
que burden [15]. As our understanding of the complexity
of atherosclerotic occlusive disease is evolving (through
enhanced use of imaging techniques and growing evidence
about molecular mechanisms), new technologies and tech-
niques have been developed to better treat LE-PAD.
Femoropopliteal artery disease, in particular, is responsible
for the majority of cases of symptomatic LE-PAD. The
superficial femoral artery (SFA) is one of the most
dynamic vessel of the body and, for this reason, the site of
frequent failure of percutaneous strategies. The SFA
undergoes many biomechanical stresses such as torsion,
compression, flexion and extension by large muscular
groups. These factors contribute to make endovascular
treatment of this vascular bed especially challenging and
are responsible of poor long-term outcomes after percuta-
neous intervention. Although PTA results effective for the
treatment of focal iliac stenosis, pooled primary patency
rate following femoropopliteal PTA is of 77% at 1 year,
61% at 3 years, and 55% at 5 years [16]. Factors affecting
the long-term patency rates of PTA alone are disease
severity, lesion length, poor runoff, diabetes, critical limb
ischemia and clinical presentation [17]. In this vascular
bed, primary arterial patency is poor with stenting too,
despite high procedural acute success. Stent fractures at
site of excessive movement (SFA and popliteal arteries)
are frequent [18]. Moreover, ultrasound evidence of
binary restenosis ranges from 8% to 40% between 6 and
24 months [19]. Procedural success rates have been
historically lower in the setting of chronic total occlusion
that account for up to 20-40% of patients with LE-PAD
undergoing percutaneous treatment [20]. In addition, a
number of potential complications (in particular, distal
embolization, plaque shift and perforation) may contribute
to disappointing results of percutaneous approach to com-
plex infrainguinal disease. Atherectomy, by debulking and
removing atherosclerotic plaque cutting or pulverizing
atheroma, seems to be a favourable option to increase the
spectrum of treatable femoropopliteal lesions such as
ostial disease (involving profunda femoral artery), densely
calcified plaque, diffuse disease.
Directional atherectomy
The SilverHawk plaque excision system (ev3 Inc.,
Plymouth, MN) consists of two major components: a low-
profile catheter and a palm-sized drive unit with on/off
thumb switch. They are packaged separately, but used
together during the atherectomy procedure. The device is
a monorail exchange system over a 0.014 guidewire that is
currently available in 7 differents diameter and catheter
lengths to allow treatment of femoral, popliteal, tibial, and
even pedal vessels [21]. It contains a carbide cutter disc
with variable height and rotates at speeds of 8,000 rpm.
With the blade spinning, the catheter is slowly advanced
across the lesion and the excissed tissue is captured and
stored in the tip of device. The cutting sequence can be
repeated as many time as necessary to achieve the desired
degree of plaque excision. It can be used without the
adjunctive use of balloon angioplasty or stents. Significant
debulking of the lesion can be achieved without the baro-
trauma associated with the previous directional atherect-
omy catheter that uses a balloon opposite the cutting
blade to maximize plaque removal [22]. The major indica-
tions for the SilverHawk device are focal eccentric lesions,
bifurcation lesions of the infrainguinal arteries including
the common femoral artery, bypass anastomotic lesions,
and long diffuse femoropopliteal lesions including chronic
total occlusions. Unfortunately, there have been no rando-
mized clinical trials using this device comparing it to
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angioplasty. Available data come from several registries or
single-centre studies [23,24]. The largest, nonrandomized
registry, TALON (Treating Peripherals with Silver Hawk
Outcome Collections) showed excellent procedural suc-
cess rates of 97.6% and < 50% residual stenosis achieved in
94.7% of lesions; adjunctive angioplasty was used in 21.7%,
and stents were used in 6.3% of the patients. The overall
12-month freedom from target lesion revascularization
(TLR) rate was 80% [25]. The SilverHawk plaque excision
system performs ideally in heavily calcified femoropopli-
teal lesions; occlusions should be predilated with an
undersized balloon to ensure that the wire crosses intra-
luminally. There are no data supporting the use of this sys-
tem in the setting of long lesion (>15 cm) and it should be
avoided when subintimal crossing is involved [26]. Table 1.
Rotational atherectomy
The Jetstream G2 (Pathway Medical Technologies) is a
rotational aspiration atherectomy device, uniquely com-
bining rotablation with aspiration capability. The device
consists of 2 primary components: a sterile, single use
unit consisting of an electrically driven, differentially cut-
ting, aspirating, expandable catheter with a control pod
assembly, and a console, with 2 peristaltic aspiration
pumps for aspiration and infusion. Isosmolar saline solu-
tion is attached to the proximal end of the catheter using
2 dedicated lines. The removed, potentially embolic,
material is aspirated at the treatment site, via ports in the
fluted tip, into the catheter lumen, and transported to a
collection bag located on the device console [27]. The
fluted tip rotates at approximately 55,000 rpm with a
delivery system that is 8 F compatible and uses a 0.014-
inch guidewire. The device is designed to treat the wide
spectrum of disease found in patients with LE-PAD,
including hard and soft plaque, calcium, thrombus, and
fibrotic lesions. Based on limited data set, the Pathway
system appears to be effective in treating SFA athero-
sclerotic disease, including cases with the presence of sig-
nificant calcification. In a multicenter registry using the
first-generation Pathway device, 172 patients with 210
lesions in nine European centers were treated; the mean
lesion length was 35 mm with moderate to high calcium.
The primary endpoint was freedom from device-related
serious adverse events (SAEs) at 6 months. TLR at 6 and
12 months was 13% and 26%, respectively. The ABI
(Ankle- Brachial Index) increased from 0.59 ± 0.21 at
baseline to 0.77 ± 0.26 and 0.82 ± 0.26 (P < .05) at 6 and
12 months, respectively [27]. TRUE (Tissue Removal by
Ultrasound Evaluation) study evaluated the debulking
properties of this device by analyzing changes in the pla-
que volume and composition and vessel size using intra-
vascular ultrasound (IVUS) and virtual histology (VH).
Table 1 Registries of patients treated with contremporary directional atherectomy
TALON McKinsey et al Zeller et al
Study type Observational, nonrandomized,
multicenter registry
Prospective study Prospective, nonrandomized, single-
center study
Patients/Lesions 728/1,517 275/579 84/131
Lesion location SFA/below-the-knee Infrainguinal SFA/popliteal
Average lesion length 8.4 cm SFA, 9.16 cm; popliteal, 3.77 cm;
tibial, 4.64 cm
9–10.6 cm
Lesion characteristics De novo De novo Group 1, 34%;a group 2, 33%;b
group 3, 33%c
Stand-alone treatment —— 64.8% ——
Adjunctive balloon angioplasty 21.7% 24.3% 59%
Adjunctive stenting 6.3% 7.5% 6%
Primary patency (by duplex) at
12 months
—— 62.2% Group 1, 84%;a group 2, 54%;b
group 3, 54%c
18-month primary patency —— 52.7% Group 1, 73%;a group 2, 42%;b
group 3, 49%c
TLR at 12 months 80% —— Group 1, 16%;a group 2, 44%;b
group 3, 47%c
TLR at 18 months —— —— Group 1, 22%;a group 2, 56%;b
group 3, 49%c
Claudication —— 36.7% ——
CLI —— 63.3% ——
Device-related SAEs 5.3% 4.1% 3.8%
aGroup 1 was de novo lesions.
bGroup 2 was native vessel restenosis.
cGroup 3 was in-stent restenosis.
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Freedom from target lesion revascularization (TLR) at 6
and 12 months was also evaluated. In this study atherect-
omy with the Jetstream G2 system resulted in substantial
plaque reduction by removing fibrotic and fibro-fatty pla-
que [28]. Furthermore, there were no major complica-
tions during the procedure or index hospitalization, and
an acceptable TLR rate was observed after a 1-year fol-
low-up. Table 2.
Orbital atherectomy
Diamondback 360° Orbital Atherectomy System, OAS,
(Cardiovascular Systems, Inc. [CSI], St. Paul, MN) is an
orbital atherectomy system that consists of an eccentric,
diamond-grit-coated, abrasive crown that creates an abla-
tive surface proportional to the displaced radius of the
crown through centrifugal force when the device is
rotated at various speeds [29]. It can create a lumen that
is > 1.75 times the crossing profile depending on the size
of the grit and the eccentricity of the offset. The greater
the speed of the crown, the larger the arc of debulking is
and, ultimately, the resultant lumen size [30]. The centri-
fugal force and the differential sanding allow the remov-
ing of thin layer of the calcific plaque to each pass of the
device while the differential sanding discriminates
between the calcific or fibrocalcific lesion and the normal
arterial wall thanks to the elastic compliance of the arter-
ial tissue adjacent to the plaque. OAS is a system which
includes a low profile catheter with an eccentrically
mounted diamond-coated crown, a control handle with
control knob, a flexible drive shaft, and a protective
sheath. The mechanism of OAS is based on the rotation
of the flexible drive shaft and of the crown over a guide
wire (ViperWire Advance). The guide wire operates in
this way as the rail on which the catheter rotates, while
the sheat covers the drive shaft and allows the delivery of
saline solution and medications in the treatment area.
The movement and the rotating speed of the crown is
managed through the external control unit. The control
unit is the user interface and regulates air pressure to
drive the speed turbine located in the control handle
rotating the drive shaft and the crown to speed up to
20.000 rpm. A constant flow of saline solution is deliv-
ered by a roller pump in the control unit which lubrifi-
cates the device and helps to flush the artery. The high
speed rotation, together with the diamond coated crown
modifies the morphology of the fibrocalcific plaque and
acts as an orbital atherectomy sanding the profile of the
lesion at each pass of the device. This device uniquely
delivers 360° of plaque removal and may be effective in
calcified plaque [31]. The off-centered shape of the
crown allows for continuous blood flow around the
device, which allows particles to move downstream, and
reduces localized heating of the vessel [30]. OASIS (Orbi-
tal Atherectomy System for the Treatment of Peripheral
Table 2 Registries of patients treated with rotational and orbital atherectomy





OASIS trial PAD II
Patients/lesions 15/15 172/210 124/201 66/86
Lesion location 47% SFA 64% SFA 94% popliteal and
tibial
Reference vessel diameter of 1.5–4
mm
Mean lesion length 61 mm 35 mm 30 mm 35 mm
Calcified —— —— 55% ——
Chronic total occlusion —— —— 12% ——
Stand-alone treatment 6 (40%) 33% 58.2% 39.5%
Adjunctive balloon angioplasty 7 (47%) 59% 39.3% 60.5%
Adjunctive stenting 2 (13%) 7% 2.50% ——
Primary patency (by duplex) at 6
months
73% —— —— ——
TLR at 6 months 0% 13% 2.4% 13.6%
TLR at 12 months —— 26% —— ——
Preprocedure ABI 0.54 ± 0.3 0.59 ± 0.2 0.68 ± 0.2 ——
ABI at 6 months 0.81 ± 0.2 0.77 ± 0.3 0.82 ± 0.1 ——
ABI at 12 months —— 0.82 ± 0.3 —— ——
MAEsa at 1 month —— —— 4 (3.2%) ——
MAEsa at 6 months 15% 13 (10.4%) 37.9%
Device-related SAEs 2.9% 6%
aDeath, myocardial infarction, amputation, or repeat revascularization.
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Vascular Stenosis), a nonrandomized prospective Investi-
gational Device Exemption study, enrolled 124 patients
(202 lesions) at 17 sites in the United States between Jan-
uary 2006 and January 2007; procedural success (achieve-
ment of < 30% residual diameter stenosis) was met in
90.1% of lesions. Orbital atherectomy was used alone in
57.7% of lesions, with adjunctive therapy (PTA and/or
stenting) used in 42.3%. Symptom- driven TLR at
6 months was 2.4%; the mean Rutherford categories were
3 ± 1.3 at baseline and 1.2 ± 1.5 at 6 months. Interest-
ingly, 14% of the patients demonstrated worse ABI at the
end of 30 days compared to baseline. This detriment in
ABI may be secondary to procedural complications due
to hemolysis or distal embolization [32]. Obviously, this
procedure can imply different intra-procedurals compli-
cations. Slow flow is a common complication in every
kind of atherectomy procedure for the liberation of deb-
ris clogging microcirculation. Several testing in vivo were
conducted to evaluate the impact of sanding and of lib-
eration of debris during the orbital atherectomy. Both the
classic and the solid crown were tested in this sense, and
both showed to generate particles of a diameter smaller
than 9.5 micron which is the diameter of the capillars.
Therefore the most of the particles can be flushed
through the capillary bed. The effect of the generation of
the particles during the procedure, however, can be mini-
mized ensuring proper orbital sanding technique and
using vasodilators. Orbital sanding speed should be
increased gradually and for short period of time, while
vasodilators drugs should be used at the beginning of the
procedure and during intervals helping the dispersion of
particles. Hemolysis is another complication associated
to high-speed orbital atherectomy. Nevertheless studies
in orbital sanding system showed a minimal and transient
haemolysis. OASIS trial did not show clinical significant
hemolysis associated to OAS atherectomy, and even if
laboratory markers did fluctuated after the procedure,
this changes were transient and resolved spontaneously.
Arterial spasm occurs during the procedure in the site
corresponding the orbital atherectomy or at site just adia-
cent. Pain can occur in the site of the treatment and it is
most likely due to the activation of the adventitial nerve
receptors as the media and intima are not innervated.
Obviously the choise of proper crown dimension and
limiting the orbital speed can prevent the onset of pain
reducing, in this way, the diameter of the rotation so that
diminishing the contact between the crown and the wall
of the vessel. The contraindications to the use of OAS
atherectomy are the presence of thrombus or dissection,
intra-stent or intra-graft stenosis, and caution should be
used in vessels with severe tortuosity. In conclusion, OAS
represents a safe, efficacious and cost-effective endovas-
cular method for LE-PAD treatment. Its use should be
implemented from the correct evaluation of the proper
device and from the choose of proper drug treatment to
improve the treatment success and to minimize the peri-
procedural adverse events. Table 2.
Atherectomy and restenosis: molecular mechanisms and
clinical outcomes
This review shows the great improvement in PAD man-
agement due to percutaneous treatment. Actually, even if
all the techniques discussed below have a good therapeutic
impact in terms of regression of LE-PAD as well as in
term of days of recovery, they all suffer of an important
limitation, the restenosis of the treated area. This draw-
back is reported in up to 60% of primarily successful PTA
[33]. Regardless of the type of intervention, stenosis or
restenosis develops in a significant number of patients,
often leading to limb loss or death and it remains the
“Achille’s heel” of the application of these procedures.
Restenosis is arbitrarily defined as a greater than 50% nar-
rowing of vessel diameter compared with a reference
artery. The clear mechanism of restenosis is not perfectly
known but several evidences suggest a strong link between
restenosis itself and vessel inflammation. This theory is
feeding the interest toward the identification of makers of
inflammations, which may have a diagnostic but especially
prognostic role in the managing of the vessels restenosis.
The plasma proteins, C-reactive protein (CRP), serum
amyloid A (SAA), and fibrinogen are sensitive, specific,
and fast reacting markers of acute phase reaction [34] and
provide an indirect measure of a cytokine dependent
inflammatory process of the arterial wall [35]. Restenosis
is mainly due to excessive neointima formation [12]. Per-
cutaneous intervention leads to mechanical injury that
induces vascular inflammation, which stimulates vascular
smooth muscle cell proliferation and extracellular matrix
deposition, resulting in neointimal thickening and resteno-
sis [36]. It has been demonstrated that in a rat model of
carotid artery dilation by a balloon catheter, the first step
in allowing vascular smooth muscle cell (SMC) prolifera-
tion from the tunica media to the intima is the occurrence
of internal elastic lamina (IEL) rupture [12]. During arter-
ial catheterization, the endothelial layer is removed by bal-
loon dilation, resulting in the loss of this important anti-
thrombogenic layer. Moreover, endothelial denudation
results in the exposure of the subendothelial matrix to
flowing blood. Platelets and fibrinogen immediately adhere
to the surface of the injured vessel, inducing platelets
aggregation and activation. Activated platelets release
various cytokines, chemokines, and growth factors, which
initiate smooth muscle cell (SMC) proliferation and leuko-
cyte recruitment to the injured vessel segment. Substances
released or activated after injury include platelet-derived
growth factor (PDGF), transforming growth factor (TGF)-
b, interleukin (IL)-1, IL-6, IL-8, thrombin, adenosine
diphosphate, and thromboxane A2 [33,37]. The initial
Franzone et al. BMC Surgery 2012, 12(Suppl 1):S13
http://www.biomedcentral.com/1471-2482/12/S1/S13
Page 5 of 9
tethering and rolling of leukocytes on platelets is mediated
through binding of the leukocyte receptor P-selectin glyco-
protein ligand-1 to platelet P-selectin. Rolling leukocytes
stop and firmly attach to adherent platelets when the leu-
kocyte integrin Mac-1 (CD11b/CD18) binds to platelet
glycoprotein Ib-alpha or to fibrinogen bound to the plate-
let glycoprotein IIb/IIIa [36]. After, there is smooth muscle
cell (SMC) proliferation and migration to the intima.
Migrated smooth muscle cells (SMCs) contribute to the
intimal thickening by the excessive synthesis of extracellu-
lar matrix (ECM) and proliferation. Intimal SMCs are
derived primarily from the media, but they may also be
derived from adventitial myofibroblasts, pericytes asso-
ciated with infiltrating microvessels, and circulating pro-
genitor cells. The pathway for SMC proliferation is an
integrated mechanism involving several known and as yet
unidentified cell-signalling pathways coupled to the cell
cycle. Peptides binding to tyrosine kinase receptors are
possibly the most potent mitogens for smooth muscle
cells (SMCs) and they modulate a variety of signalling
pathways, including ras [38], raf, the mitogen activated
protein kinase (MAPK) cascade, the phosphoinositol-3
kinase- protein kinase B pathway and the diacylglycerol
protein kinase C pathway [35,39,40]. It was previously
described the opposite effects of SMCs proliferation of
two intracellular pathways. In fact, it was showed that the
stimulation of Ras-MAPKs proteins induces the prolifera-
tion of SMCs [38,34] that are, in contrast, inhibited by the
activation of cAMP-PKA signaling [41,42]. Furthermore
hyperinsulinemia, through activation of the ras–MAPK
pathway, rather than hyperglycemia per se, appears to be
crucial in determining the exaggerated neointimal
response after balloon angioplasty in diabetic animals [43].
Moreover, new growing knowledge about molecular
mechanism of restenosis highlight the role of micro-RNA
in vascular remodeling [44].
Several studies show the rate of restenosis after baloon
angioplasty, after stent implantation and after atherect-
omy using different types of devices. Ablative therapy
deserves particular relevance and several studies have
investigated the rates of occurrence of restenosis after
debulking procedures. TALON (Treating Peripherals
with Silver Hawk Outcome Collections) study involved
601 patients showing a rate of survival free of TLR at
6 months of 90% and at 12 months of 80% [25]. Sarac et
al. recruited 167 patients treated with Silver Hawk device
in tibial arteries. Cumulative 1-year primary and second-
ary patency rates were 43% and 57%, respectively [45].
An interesting result comes from Shammas et al. trial
which demonstrates the inferiority of Silver Hawk ather-
ectomy versus balloon angioplasty. In this trial 72
patients were divided in two groups. The first group
(n=38) were treated with Silver Hawk atherectomy, the
second group (n=35) were treated with conventional
balloon angioplasty. Primary patency at 2 months was of
34% in the first group versus 56% in the second group
[46]. Another kind of device was investigated from Schei-
ner et al. who studied the impact of Laser ablative ather-
ectomy in SFA arteries. They reported their experience
with the excimer laser in recanalizing occluded SFA
arteries: the technical success was 90.5%, but primary
patency at 1 year was only 33.6%. The 1 year assisted pri-
mary and secondary patency rates were 65.1% and 75.9%,
respectively. In addition, short SFA occlusions (1–10 cm)
treated with the excimer laser demonstrated primary,
assisted primary, and secondary patency rates of 49.2%,
76.5%, and 86.3%, respectively, at 36-month follow-up
[47]. Stoner et al. reported their data on 40 patients trea-
ted with laser atherectomy; average follow-up was 461 ±
49 days. The indication for laser atherectomy was critical
limb ischemia in 26 (65%) and claudication in 11 (35%)
patients. A total of 47 lesions in the femoropopliteal and
infrapopliteal arterial segments were treated. Adjunctive
angioplasty was used in 75% of cases. The overall
12 month primary patency was 44% [48]. Two further
trials investigated rotational atherectomy: Myers et al.
treated 72 patients using rotablator and showed a pri-
mary patency of 47% at 6 months, 31% at 12 months and
of 18,5% at 24 months [49]. In the OASIS TRIAL, rota-
tional atherectomy with Diamondback 360° was asso-
ciated with a rate of TLR of 0,9% at 6 months, but
further data are needed to understand the impact of this
device on long term patency.
Procedural risks and complications: how to optimize
peripheral atherectomy
The risks associated with atherectomy of the superficial
femoral, popliteal, anterior tibial, posterior tibial and pero-
neal arteries may include, but are not limited to the fol-
lowing: arterial dissection, arterial perforation, arterial
rupture, arterial spasm, arterio-venous (AV) fistula, bleed-
ing complications, embolism and/or arterial thrombosis,
emergency or non-emergency arterial bypass surgery,
entry site complications, restenosis of the treated segment,
total occlusion of the peripheral artery, vascular complica-
tions which may require surgical repair [50,51] . As with
any device requiring mechanical deployment and retrac-
tion, there exists a risk of mechanical failure of the device
resulting in potential surgical intervention. All of the
above could cause prolonged illness, permanent impair-
ment of daily function or, in rare cases, death. Possible
treatments could include vascular surgery. Extensive relia-
bility engineering testing has been performed on the study
device to mitigate risks to the subject due to product fail-
ure. Risks of atherectomy may be further limited by pro-
viding medications such as aspirin or clopidogrel and
continuing to monitor subjects following atherectomy
[52,53]. Mechanical atherectomy may be associated with
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high risk of peripheral embolization. The risk of distal
embolization is more common in the acute and subacute
peripheral vascular intervention. Embolic protection
devices (EPD) have been used successfully in many cir-
cumstances. In the femoropopliteal system the size of the
common femoral can vary (3-6 mm), then some vessel are
too small for most distal protection. The maximum dia-
meter is 5 to 6.3mm depending upon the device used [54].
The use of EPD in acute lower-extremity ischemia is con-
sidered a reasonable strategy to prevent distal thrombo-
embolism and occlusion of the distal circulation [52]. The
embolization rate reported by TALON registry was 0.1%
[25]. The use of distal filter has been always associated to
retrievement of debris consisting of atherectomy-cut pieces
of plaque [55]. In the PROTECT (Preventing Lower Extre-
mity Distal Embolization Using Embolic Filter Protection)
registry 40 patients with 56 lesions underwent angioplasty/
stenting or atherectomy, with 1 filter employed per patient.
Clinically significant macrodebris (>2 mm in diameter) was
found in 27.6% of the angioplasty/ stenting patients and
90.9% of the atherectomy patients [56]. Some recommen-
dations to optimize the result of peripheral atherectomy
and minimize the risk of procedural complications are
listed below: use contralateral access in most cases but, for
distal lesions, prefer an antegrade approach for a better
control of tip; make slow and methodical cuts and advance
the cutting blade slowly; ensure adequate anticoagulation
(ACT, activated clotting times of 275 to 300 seconds) to
avoid thrombotic complications during the procedure.
Conclusions
Recent technological advances have made it possible to
increase the spectrum of treatable peripheral arterial
lesions with high acute procedure success rates. However,
the choice of the best endovascular strategy for the treat-
ment of LE-PAD still remains challenging because of the
specific features of this vascular bed and the diffuse nature
of the atherosclerotic process. Durability and long-term
patency remain the major challenges to therapy in LE-
PAD endovascular treatment significant advances: despite
significant advances and availability of new devices, the
principal failure continues to be recurrent restenosis . The
role of atherectomy may be to overcome the limitation of
balloon angioplasty and stent placement. A number of
debulking modalities and devices are now available with
good procedural results. Long term outcomes need to be
addressed by large, randomized trials.
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